CBD anxiety trial for brain cancer patients ends early
NCT ID NCT05753007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if a high-CBD hemp product could reduce anxiety and improve quality of life in people newly diagnosed with glioblastoma, a serious brain tumor. The trial planned to compare the CBD product to a placebo over 8 weeks, but it was stopped early after only 2 people enrolled. No conclusions can be drawn from this small, incomplete study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California San Francisco Brain Tumor Center
San Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a One-Two punch slow recurrent brain cancer?